This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2015 Apr;74(4):791-2.

doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

Jens Y Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Tobias Alexander¹, Falk Hiepe¹, Andreas Radbruch², Gerd-Rüdiger Burmester¹, Gabriela Riemekasten¹

Affiliations

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
² German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany.

PMID: 25609413
DOI: 10.1136/annrheumdis-2014-206506

Case Reports

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

Jens Y Humrich et al. Ann Rheum Dis. 2015 Apr.

. 2015 Apr;74(4):791-2.

doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

Authors

Jens Y Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Tobias Alexander¹, Falk Hiepe¹, Andreas Radbruch², Gerd-Rüdiger Burmester¹, Gabriela Riemekasten¹

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
² German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany.

PMID: 25609413
DOI: 10.1136/annrheumdis-2014-206506

No abstract available

Keywords: Cytokines; Systemic Lupus Erythematosus; T Cells; Treatment.

PubMed Disclaimer

Similar articles

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B, Lindholm C, Pullerits R. Jovancevic B, et al. Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23. Lupus. 2013. PMID: 23612795 Review.
Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.
Brasileiro A, Fonseca Oliveira J, Pinheiro S, Paiva-Lopes MJ. Brasileiro A, et al. Lupus. 2016 May;25(6):663-5. doi: 10.1177/0961203316630116. Epub 2016 Feb 3. Lupus. 2016. PMID: 26846694
Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y. Iwata S, et al. J Rheumatol. 2011 Apr;38(4):633-41. doi: 10.3899/jrheum.100729. Epub 2010 Dec 15. J Rheumatol. 2011. PMID: 21159836
Newer therapeutic approaches for systemic lupus erythematosus.
Ginzler EM, Dvorkina O. Ginzler EM, et al. Rheum Dis Clin North Am. 2005 May;31(2):315-28. doi: 10.1016/j.rdc.2005.01.003. Rheum Dis Clin North Am. 2005. PMID: 15922148 Review.
Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy.
Kok MR, Vos K, Bos JD, Tak PP. Kok MR, et al. J Clin Rheumatol. 2010 Oct;16(7):345. doi: 10.1097/RHU.0b013e3181f4e4b7. J Clin Rheumatol. 2010. PMID: 20859218 No abstract available.

See all similar articles

Cited by

Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.
Dörner T, Lipsky PE. Dörner T, et al. Nat Rev Rheumatol. 2016 Nov;12(11):645-657. doi: 10.1038/nrrheum.2016.158. Epub 2016 Oct 13. Nat Rev Rheumatol. 2016. PMID: 27733759 Review.
Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.
Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E, Papadopoulou A. Christofi P, et al. Cancers (Basel). 2023 Dec 17;15(24):5877. doi: 10.3390/cancers15245877. Cancers (Basel). 2023. PMID: 38136421 Free PMC article. Review.
[IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].
Humrich JY, Riemekasten G. Humrich JY, et al. Z Rheumatol. 2016 Jun;75(5):490-2. doi: 10.1007/s00393-016-0129-8. Z Rheumatol. 2016. PMID: 27250490 German. No abstract available.
Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis.
Zhang SX, Wang J, Wang CH, Jia RH, Yan M, Hu FY, Liu GY, Liu XY, Luo J, Gao C, Li XF. Zhang SX, et al. Ther Adv Musculoskelet Dis. 2021 Apr 28;13:1759720X211011370. doi: 10.1177/1759720X211011370. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 33995604 Free PMC article.
The emerging role of regulatory cell-based therapy in autoimmune disease.
Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M, Rezaei-Tazangi F, Khorram R, Afshinpour M, Robino RA, Aref AR, Ferreira LMR. Ghobadinezhad F, et al. Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022. Front Immunol. 2022. PMID: 36591309 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information